Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes
1. In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial ...
Tag: major adverse cardiovascular events (MACE)
Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin
1. In this multi-database retrospective cohort study, rosuvastatin was found to be associated with slightly decreased risk of all-cause mortality ...
The presence of a fractional flow reserve-negative high-risk nonculprit plaque associated with worse clinical outcomes among patients with myocardial infarction
1. Major adverse cardiovascular events (MACE) were more likely to occur in patients with myocardial infarction (MI) with an optical ...
Bempedoic acid reduces the risk of major adverse cardiovascular events
1. In this randomized controlled trial, bempedoic acid significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with increased cardiovascular ...
Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
1. Risk of major adverse cardiac events increased amongst patients with a specific glomerular disease, including non-proliferative glomerulopathy, renal vascular ...
Chlorthalidone is not superior to hydrochlorothiazide in preventing hypertension-related cardiovascular events
1. Patients with hypertension who received chlorthalidone did not have a lower occurrence of adverse cardiovascular outcomes compared to patients ...
CT associated with lower complication risks than invasive coronary angiography
1. In patients with stable chest pain and intermediate pretest probability of coronary artery disease (CAD), there was no difference ...